Brooke McCormick

Refat Rasul Srejon, MPH, recommends employer coverage for substance use care and follow-up, plus research on local treatment and drug trends.

Although rarely used in psoriatic arthritis (PsA), combination targeted therapy (CTT) appears to have a safety profile comparable to standard therapy.

Refat Rasul Srejon, MPH, says reducing opioid-related emergency department (ED) visits among young adults requires strategies like medication-assisted treatment and targeted outreach.

Increased use of neoadjuvant chemotherapy (NACT) with interval debulking surgery has changed surgical practice patterns, improving complete resection rates and reducing postoperative complications.

Refat Rasul Srejon, MPH, found that Affordable Care Act (ACA) dependent coverage had mixed effects on young adults’ substance-related emergency department (ED) visits.

The 2024-2025 influenza season saw record-high hospitalization rates, prompting the CDC to emphasize the importance of vaccination and early antiviral treatment.

Ovarian and uterine cancers linked to high body mass index (BMI) have steadily increased among women of reproductive age, with the greatest burden observed in low- and middle-sociodemographic index regions.

From respiratory conditions to rare diseases and beyond, here are 5 groundbreaking FDA approvals from last month.

Patients with bronchiectasis who are highly symptomatic face an increased risk of future exacerbations, suggesting symptoms should guide prevention strategies.

Adults with food insecurity report higher rates of long COVID and lower recovery, with Supplemental Nutrition Assistance Program (SNAP) participation and employment status affecting these associations.

Extended hospital stays among Medicare Advantage beneficiaries translated to an estimated 1.8 million additional hospital bed days in 2022.

While body mass index (BMI) accurately identified excess adiposity in nearly all children and adolescents with obesity, it failed to detect many of those without obesity who still had excess body fat.

Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).

Ovarian cancer deaths remain uneven across age, geography, and racial and ethnic groups, highlighting the need for targeted interventions.

The FDA has approved rilzabrutinib (Wayrilz; Sanofi) as a groundbreaking treatment for immune thrombocytopenia (ITP), enhancing patient outcomes and quality of life.

Patients with chronic obstructive pulmonary disease (COPD) who smoke were less likely to receive tobacco dependence treatment (TDT) if they lived in rural areas or had longer travel times to care, highlighting persistent geographic disparities in access.

Neoadjuvant chemotherapy followed by interval cytoreductive surgery significantly improves survival rates in patients with advanced ovarian cancer compared with chemotherapy alone.

Housing assistance significantly reduces medical financial hardship for renters with a history of cancer, enhancing their financial security and access to care amid rising health costs.

Many patients later diagnosed with high-grade serous cancer had prior surgical or genetic testing opportunities that could have reduced their ovarian cancer risk, underscoring the need to expand opportunistic salpingectomy and preventive strategies.

In the final clip, James D. Chalmers, MBChB, PhD, notes that while the FDA approval of brensocatib is a milestone, questions remain on optimal patient selection, long-term benefits, and further targeting inflammation.

The definition of comprehensive non-small cell lung cancer (NSCLC) testing is rapidly evolving with new biomarkers and therapies, according to Julia Rotow, MD, creating added challenges for community practices.

In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.

Renal denervation modestly lowers blood pressure, with durable long-term benefits, according to Deepak L. Bhatt, MD, MPH, MBA.

Brensocatib, the first FDA-approved dipeptidyl peptidase 1 (DPP1) inhibitor for non–cystic fibrosis bronchiectasis, may have broader potential for other neutrophil-driven conditions, according to James D. Chalmers, MBChB, PhD.

James Chalmers, MBChB, PhD, highlights the reassuring safety and tolerability profile of brensocatib in patients with non–cystic fibrosis bronchiectasis.

James D. Chalmers, MBChB, PhD, explains that the ASPEN trial findings show that brensocatib reduces exacerbations, slows lung function decline at higher doses, and offers clinicians a long-awaited evidence-based treatment option.

Climate-related disasters threaten US drug production, highlighting vulnerabilities in the pharmaceutical supply chain and the urgent need for strategic planning.

Today, the FDA issued a complete response letter (CRL) for vatiquinone (PTC Therapeutics), delaying its potential approval as a treatment for Friedreich ataxia amid efficacy concerns.

Research reveals a significant decline in reported conflicts of interest among the CDC's and FDA's vaccine advisory committees, challenging Robert F. Kennedy Jr's claims.

Public awareness of human papillomavirus (HPV) and its link to cervical and oral cancers is alarmingly low in the US, especially in the Midwest and South.